The one peptide with FDA-approved human data for selectively reducing visceral fat is tesamorelin — and while GLP-1 medications like semaglutide and tirzepatide cut far more total fat, they don’t target the visceral depot specifically and they cost you some muscle along the way. Understanding how those two tools differ is the key to thinking clearly about deep abdominal fat, rather than chasing whatever a clinic is selling.
Visceral fat is worth singling out because it is the fat most tied to metabolic risk. What follows is an honest account of which peptide actually has evidence here, what GLP-1 drugs do to fat and muscle, and where the two might fit together — including where the evidence runs out.
What is visceral fat, and why single it out?
Visceral adipose tissue is the deep fat packed around the abdominal organs, distinct from the subcutaneous fat directly under the skin. It is metabolically active and more strongly associated with insulin resistance, elevated triglycerides, and cardiometabolic risk. That is why a targeted reduction in visceral fat — even without a dramatic change on the scale — can matter more than the number it moves.
Which peptide actually targets visceral fat?
The honest answer is one: tesamorelin. It is a stabilized growth-hormone-releasing hormone analog that prompts the pituitary to release growth hormone, and in its pivotal trial it reduced visceral adipose tissue by about 15% over 26 weeks while barely touching the fat under the skin (Falutz et al., N Engl J Med 2007). A separate randomized trial showed it also lowered liver fat (Stanley et al., JAMA 2014).
The essential caveat: tesamorelin is FDA-approved only for HIV-associated lipodystrophy (FDA label). Using it for general visceral fat is off-label, its effect reverses when you stop, and it raises IGF-1, so it is contraindicated in active malignancy and requires monitoring. Other growth-hormone-axis peptides share the mechanism but do not have this selective visceral-fat evidence.
How do GLP-1 medications affect visceral fat?
GLP-1 and dual GIP/GLP-1 medications work differently — they reduce appetite and drive large overall weight loss, and that includes substantial reductions in total fat mass, visceral fat among it. In the trials, total fat falls sharply. The trade-off is body composition: a meaningful fraction of the weight lost is lean mass, on the order of 25–40% depending on the drug and analysis (Neeland et al., Diabetes Obes Metab 2024). Fat loss still outpaces muscle loss, but muscle has to be actively protected. We cover that in preventing muscle loss on GLP-1 and peptides for preserving muscle.
So the two tools have different shapes. GLP-1 medications move the most total fat but are not visceral-specific and pull down lean mass. Tesamorelin moves less total fat but is visceral-selective and, if anything, supports lean tissue.
Where the two might fit together
| GLP-1 / GIP medications | Tesamorelin (GHRH analog) | |
|---|---|---|
| Primary effect | Large total weight & fat loss | Selective visceral-fat reduction |
| Visceral-specific? | No — reduces fat broadly | Yes |
| Effect on muscle | Lean mass falls unless protected | Supports lean tissue |
| FDA-approved for fat loss? | Yes (obesity / overweight) | Only in HIV lipodystrophy |
| Reversible on stopping | Weight tends to return | Visceral fat returns |
The logic some clinicians follow is to pair them: use a GLP-1 medication for total fat loss while protecting muscle with training and protein, and consider tesamorelin where deep abdominal or liver fat is the specific concern. It is a reasonable hypothesis grounded in each drug’s mechanism — but be clear-eyed that no large randomized trial has tested this combination, so it remains an off-label, individualized decision, not a validated protocol.
Who is this reasonable for?
It fits adults whose real target is visceral or liver fat and its metabolic consequences, who are working within a licensed clinical relationship, and who will measure the result — baseline labs (including IGF-1, triglycerides, and glucose) and, ideally, imaging or a body-composition scan, then a re-test. It is not appropriate in pregnancy or active malignancy, and growth-hormone-axis peptides can raise blood sugar, which needs watching alongside any metabolic medication.
How Trellis approaches visceral fat
Trellis Vitality is the accessibly-priced, patient-first alternative to premium-gated longevity clinics — on-demand and at home, without a five-figure annual membership. Where a peptide or a GLP-1 medication fits, it is prescribed through a licensed clinical flow, with off-label status stated plainly and compounded medications dispensed by a licensed pharmacy.
Every protocol opens with a free Vitality Lab Kit and baseline labs, so the decision to start and continue rests on your own metabolic markers — not a waistline promise. If you want the deeper mechanism, start with what tesamorelin is.
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; use for general visceral fat is off-label. Peptides and, where applicable, compounded medications are prescribed within a licensed clinical relationship and prepared by a state-licensed, FDA-regulated compounding pharmacy. Compounded medications are not FDA-approved as finished products, and nothing here is a promise of results or a treatment for any disease.
Peptides for visceral fat FAQ
What peptide is best for visceral fat? Tesamorelin is the only peptide with FDA-approved human trial data showing selective reduction of visceral abdominal fat. Its approval is limited to HIV-associated lipodystrophy, so other use is off-label.
Do GLP-1 medications reduce visceral fat? Yes. Semaglutide and tirzepatide produce large reductions in total fat mass, including visceral fat. The trade-off is that a meaningful share of the weight lost is lean mass unless muscle is protected with resistance training and protein.
Can you combine a peptide like tesamorelin with a GLP-1 medication? Some clinicians pair them — GLP-1 for total fat loss, tesamorelin for selective visceral targeting — but no large randomized trial has tested that combination, so it is an off-label, case-by-case decision made with a clinician and anchored to labs.
Why does visceral fat matter more than other fat? Visceral fat sits around the abdominal organs and is metabolically active, so it is more strongly linked to insulin resistance, high triglycerides, and cardiometabolic risk than the subcutaneous fat under the skin.
Is using peptides for visceral fat FDA-approved? Only for one narrow use: tesamorelin in HIV-associated lipodystrophy. Using peptides for general visceral-fat reduction is off-label and should be supervised.
The measured way to decide is to look at your own numbers first. Begin your assessment →
Sources
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. https://jamanetwork.com/journals/jama/fullarticle/1889139
- EGRIFTA (tesamorelin for injection) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505Orig1s010lbl.pdf
- Neeland IJ, et al. Changes in lean body mass with GLP-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728